Bereich
Brustzentrum St.Gallen
BZ · Dept. IV
Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II)
Reinartz S, Sabbatini P, DuBois A, Kreienberg R, Möbus V, Huober J, Renke K, Giffels P, Krista K, Schlebusch H, Köhler S, Wagner U. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clinical cancer research : an official journal of the American Association for Cancer Research 2004; 10:1580-7.
01.03.2004Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II)
01.03.2004Clinical cancer research : an official journal of the American Association for Cancer Research 2004; 10:1580-7
Reinartz Silke, Sabbatini Paul, DuBois Andreas, Kreienberg Rolf, Möbus Volker, Huober Jens, Renke Kirsten, Giffels Patrick, Krista Karl, Schlebusch Harald, Köhler Siegmund, Wagner Uwe
Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab
Weder P, Anliker M, Itin P, Bargetzi M. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab. Dermatology 2004:3-281.
16.02.2004Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab
16.02.2004Dermatology 2004:3-281
Weder Patrik, Anliker Mark, Itin P, Bargetzi M
Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab
Weder P, Anliker M, Itin P, Bargetzi M. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab. Dermatology (Basel, Switzerland) 2004; 208:281-3.
01.01.2004Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab
01.01.2004Dermatology (Basel, Switzerland) 2004; 208:281-3
Weder Patrik, Anliker M, Itin P, Bargetzi M
Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations
Mueck A, Seeger H, Wallwiener D, Huober J. Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations. European journal of gynaecological oncology 2004; 25:699-701.
01.01.2004Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations
01.01.2004European journal of gynaecological oncology 2004; 25:699-701
Mueck A O, Seeger H, Wallwiener D, Huober Jens
Überblick über die neoadjuvante endokrine Theraphie des rezeptorpositiven Mammakarzinoms der postmenopausalen Frau
Paepke S, Eiermann W, Wolf C, Huober J, Warm M, Blohmer J, Diedrich F, Fischer T, Pildner v Steinburg S, Schwarz-Böger U, Jacobs V, Harbeck N, Kiechle M. Überblick über die neoadjuvante endokrine Theraphie des rezeptorpositiven Mammakarzinoms der postmenopausalen Frau. Geburtsh Frauenheilk 2004; 64:1290-1298.
01.01.2004Überblick über die neoadjuvante endokrine Theraphie des rezeptorpositiven Mammakarzinoms der postmenopausalen Frau
01.01.2004Geburtsh Frauenheilk 2004; 64:1290-1298
Paepke S, Eiermann W, Wolf C, Huober Jens, Warm M, Blohmer J, Diedrich F, Fischer T, Pildner v Steinburg S, Schwarz-Böger U, Jacobs VR, Harbeck N, Kiechle M
Aktueller Stellenwert des Ultraschalls in der Mammadiagnostik
Krainick-Strobel U, Bergmann A, Huober J, Wallwiener D. Aktueller Stellenwert des Ultraschalls in der Mammadiagnostik. Geburtsh Frauenheilk 2004; 64:632-633.
01.01.2004Aktueller Stellenwert des Ultraschalls in der Mammadiagnostik
01.01.2004Geburtsh Frauenheilk 2004; 64:632-633
Krainick-Strobel U, Bergmann A, Huober Jens, Wallwiener D
Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer
Senn H, Thürlimann B, Goldhirsch A, Wood W, Gelber R, Coates A. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. Breast (Edinburgh, Scotland) 2003; 12:569-82.
01.12.2003Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer
01.12.2003Breast (Edinburgh, Scotland) 2003; 12:569-82
Senn H-J, Thürlimann Beat, Goldhirsch A, Wood W C, Gelber R D, Coates A S
The importance of evidence-based international consensus in the primary treatment of breast cancer--a periodic 'must'
Senn H, Thürlimann B. The importance of evidence-based international consensus in the primary treatment of breast cancer--a periodic 'must'. Breast (Edinburgh, Scotland) 2003; 12:349-50.
01.12.2003The importance of evidence-based international consensus in the primary treatment of breast cancer--a periodic 'must'
01.12.2003Breast (Edinburgh, Scotland) 2003; 12:349-50
Senn Hans-Jörg, Thürlimann Beat
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
Thürlimann B, Robertson J, Nabholtz J, Buzdar A, Bonneterre J, Arimidex Study Group. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. European journal of cancer (Oxford, England : 1990) 2003; 39:2310-7.
01.11.2003Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
01.11.2003European journal of cancer (Oxford, England : 1990) 2003; 39:2310-7
Thürlimann Beat, Robertson J F R, Nabholtz J M, Buzdar A, Bonneterre J, Arimidex Study Group
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer
Goldhirsch A, Wood W, Gelber R, Coates A, Thürlimann B, Senn H. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:3357-65.
01.09.2003Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer
01.09.2003Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:3357-65
Goldhirsch Aron, Wood William C, Gelber Richard D, Coates Alan S, Thürlimann Beat, Senn Hans-Jörg
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
Nabholtz J, Bonneterre J, Buzdar A, Robertson J, Thürlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. European journal of cancer (Oxford, England : 1990) 2003; 39:1684-9.
01.08.2003Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
01.08.2003European journal of cancer (Oxford, England : 1990) 2003; 39:1684-9
Nabholtz J M, Bonneterre J, Buzdar A, Robertson J F R, Thürlimann Beat
Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann B, Goldhirsch A, Brunner K, Borner M, Swiss Group for Clinical Cancer Research (SAKK). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:1215-21.
01.08.2003Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
01.08.2003Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:1215-21
Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann Beat, Goldhirsch A, Brunner K W, Borner M M, Swiss Group for Clinical Cancer Research (SAKK)
Weekly paclitaxel (Taxol) with or without trastuzumab (Herceptin) in advanced breast cancer: a community-based observation study
von Moos R, Thürlimann B. Weekly paclitaxel (Taxol) with or without trastuzumab (Herceptin) in advanced breast cancer: a community-based observation study. Onkologie 2003; 26:128-32.
01.04.2003Weekly paclitaxel (Taxol) with or without trastuzumab (Herceptin) in advanced breast cancer: a community-based observation study
01.04.2003Onkologie 2003; 26:128-32
von Moos R, Thürlimann Beat
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII
Wallgren A, Collins J, Coates A, Price K, Forbes J, Werner I, Fey M, Thürlimann B, Lindtner J, Holmberg S, Castiglione-Gertsch M, Goldhirsch A, Gelber R, Bonetti M, International Breast Cancer Study Group Trials I through VII. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1205-13.
01.04.2003Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII
01.04.2003Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1205-13
Wallgren A, Collins J, Coates A S, Price K, Forbes J F, Werner I D, Fey M, Thürlimann Beat, Lindtner J, Holmberg S B, Castiglione-Gertsch M, Goldhirsch A, Gelber R D, Bonetti M, International Breast Cancer Study Group Trials I through VII
A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
Aapro M, Thürlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:291-7.
01.02.2003A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
01.02.2003Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:291-7
Aapro M S, Thürlimann Beat, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research
Effect of tamoxifen and 2-methoxyestradiol alone and in combination on human breast cancer cell proliferation
Seeger H, Diesing D, Gückel B, Wallwiener D, Mueck A, Huober J. Effect of tamoxifen and 2-methoxyestradiol alone and in combination on human breast cancer cell proliferation. The Journal of steroid biochemistry and molecular biology 2003; 84:255-7.
01.02.2003Effect of tamoxifen and 2-methoxyestradiol alone and in combination on human breast cancer cell proliferation
01.02.2003The Journal of steroid biochemistry and molecular biology 2003; 84:255-7
Seeger H, Diesing D, Gückel B, Wallwiener D, Mueck A O, Huober Jens
Chemotheraphie des Endometriumkarzinoms
Huober J, Gruber I, Fehm T. Chemotheraphie des Endometriumkarzinoms. Onkologe 2003; 9:1241-1244.
01.01.2003Chemotheraphie des Endometriumkarzinoms
01.01.2003Onkologe 2003; 9:1241-1244
Huober Jens, Gruber I, Fehm T
St. Gallen 2003 - Was tun?
Wallwiener D, Huober J. St. Gallen 2003 - Was tun?. Frauenarzt 2003; 44:516-517.
01.01.2003St. Gallen 2003 - Was tun?
01.01.2003Frauenarzt 2003; 44:516-517
Wallwiener D, Huober Jens
[CD80-modified tumor cell lines: implications for cell-based vaccinations in breast cancer patients]
Gückel B, Stumm S, Kayser S, Rentzsch C, Gruber I, Marmé A, Huober J, Meuer S, Wallwiener D. [CD80-modified tumor cell lines: implications for cell-based vaccinations in breast cancer patients]. Zentralblatt für Gynäkologie 2002; 124:566-73.
01.12.2002[CD80-modified tumor cell lines: implications for cell-based vaccinations in breast cancer patients]
01.12.2002Zentralblatt für Gynäkologie 2002; 124:566-73
Gückel B, Stumm S, Kayser S, Rentzsch C, Gruber I, Marmé A, Huober Jens, Meuer S C, Wallwiener D
Anastrozole versus progestins/tamoxifen
Thürlimann B. Anastrozole versus progestins/tamoxifen. Eur J Cancer 2002; 38 Suppl 6:S49-51.
01.11.2002Anastrozole versus progestins/tamoxifen
01.11.2002Eur J Cancer 2002; 38 Suppl 6:S49-51
Thürlimann Beat